View All Conferences
2019 Annual Meeting of the Association for Research in Vision and Ophthalmology
Basic scientists and clinical researchers from around the world will share the latest breakthroughs in vision research at ARVO 2019 in Vancouver, BC.
Brian Toy, MD: Risk Factors for Uveitis
Investigators found that female sex, older age, and certain comorbidities were associated with an increased risk of uveitis.
Brian Toy, MD: Incidence of Uveitis in the US
Using a national medical claims database, investigators found the incidence and prevalence of uveitis in the US.
Real-World Outcomes of FAc Implant
Results from the 3-year European Iluvien Registry Safety Study that examined outcomes of the fluocinolone acetonide implant compared to those of the pivotal FAME trials.
Dolly Chang, MD, PhD: Benefits of New Endpoints for Geographic Atrophy
Investigators calculated perilesional sensitivity and responding sensitivity for eyes in a geographic atrophy clinical trial and compared these to mean retinal sensitivity.
Dolly Chang, MD, PhD: Developing an Endpoint for Geographic Atrophy Research
Chang and colleagues are developing an outcome for geographic atrophy trials that measures vision loss rather than structural changes.
BAK-Free Latanoprost for Open-Angle Glaucoma, Ocular Hypertension
A study presented at ARVO 2019 examines the long-term safety of BAK-free latanoprost for treatment of open-angle glaucoma or ocular hypertension
Burnout, Intent to Leave, and Fulfillment Rates in Ophthalmology
A recent study, presented at ARVO 2019, found that ophthalmologists have 77% greater odds of experiencing professional fulfillment, but ophthalmology residents are 3 times more likely to express an intent to leave the field than other surgical residents.
Optometrists' Attitudes Towards Blue-Light Blocking Devices
A study from ARVO 2019 found that, while optometrists are likely to prescribe them, many are still split over the impact of blue light-blocking devices
Sarah Hamm-Alvarez, PhD: Importance of a Tear-Based Parkinson Biomarker
A tear-based biomarker for Parkinson disease would allow providers to diagnose the condition sooner and create a measurement tool for new drug development.
Ronald Silverman, MD: Drawing Connections from the Eye to Preeclampsia
Investigators found significant differences in ocular flow velocity between patients with preeclampsia and without who had recently given birth.
Sarah Hamm-Alvarez, PhD: Developing a Biomarker for Parkinson Disease
Identifying a potential biomarker is an extended process, one which benefits from collaboration between researchers and clinicians of many specialties.
Ronald Silverman, MD: Preeclampsia & The Eye
The placenta plays a major role in preeclampsia but is difficult to access. Investigators have turned to the eye, the choroid in particular, looking for clues about this serious condition.
Reliability of Testing Methodology for Visual Acuity, Contrast Sensitivity
Pinakin Davey, DO, PhD, discusses the findings of his study comparing reliability of testing methodologies for visual acuity and contrast sensitivity at ARVO 2019.
Low Follow-up Rates Among Homeless People Receiving Ophthalmology Referrals
People experiencing homelessness were more likely to follow-up on referrals from an ophthalmology clinic if they had finished high school or had a primary care provider.
Ziv-Aflibercept Comparable to Aflibercept, Ranibizumab
The ZEBRA study found that ziv-aflibercept was non-inferior to aflibercept and ranibizumab, and was more cost-effective.
Mia Woodward, MD: Opioid Prescribing Post-Corneal Surgery
Mia Woodward, MD, discusses the findings of her study which explored the possible over prescription and use of opioids post-corneal surgery.
The Future of Ophthalmology Depends on The Perception of Students
The field has a growing demand of care, and dropping rate of new specialists. The solution can start at medical schools.
Mia Woodward, MD: Women and Minority Groups In Clinical Trials
Mia Woodward, MD, discusses her study examining the the inclusion of women and minorities in National Eye Institute clincal trials.
Sarah Hamm-Alvarez, PhD: Comparing Basal & Reflex Tears
Investigators examined both basal and reflex tears from patients with and without Parkinson disease, in search of a potential biomarker.
Jennifer Lim, MD: The Impact of Artificial Intelligence in DR Screening
Investigator Lim sees hope that the EyeArt AI system will be able to screen more patients for diabetic retinopathy and help prevent blindness.
Sarah Hamm-Alvarez, PhD: Could Tears Hold a Parkinson Biomarker?
It’s difficult to diagnose Parkinson disease before some permanent neurological damage occurs. But tears may hold the key to earlier diagnoses.
Concussion-Related Visual Dysfunction Linked to Longer Recovery Time
Investigators found that children who experienced concussion-related visual dysfunction had a recovery time nearly twice that of those who did not.
William Freeman, MD: Creating Treatments with Compliance in Mind
William Freeman, MD, of UCSD and Shiley Eye Institute, discusses the importance of creating treatments for eye diseases that make compliance easier for patients.
William Freeman, MD: Brimonidine as a Treatment for Geographic Atrophy
William Freeman, MD, discusses the results of a study he led and other potential treatments for geographic atrophy from a session he hosted at ARVO 2019.
Pinakin Davey, DO, PhD: Novel Methods for Testing IOP
Pinakin Davey, DO, PhD, sat down with MD Magazine® at ARVO 2019 to discuss a study he led testing a handheld tonometer for testing IOP.
Jennifer Lim, MD: Results of the EyeArt Diabetic Retinopathy Screening Study
The artificial intelligence system, EyeArt, was able to detect diabetic retinopathy with a sensitivity of 95.5% and specificity of 86%.
Jonathan Myers, MD: When Should Patients with Worsening Vision Stop Driving?
Jonathan Myers, MD, of the Wills Eye Hospital, discusses a study examining the rate of car accidents among glaucoma patients.
Jennifer Lim, MD: Training & Testing AI to Detect Diabetic Retinopathy
After training the EyeArt system on thousands of images of eyes with diabetic retinopathy, investigators tested the AI in a clinical trial.
Jennifer Lim, MD: Can AI Fill the Gap in Diabetic Retinopathy Screening?
With 8.5% of the global population having diabetes, there is a growing unmet need for diabetic retinopathy screening. Artificial intelligence may help close the gap.
Charles Wykoff, MD, PhD: Results & Implications of the PANORAMA Trial
Aflibercept not only significantly improved patients’ DRSS scores, but it also reduced vision-threatening complications by 75% compared to placebo.
Charles Wykoff, MD, PhD: PANORAMA Trial Design & Patients
The trial examined 2 doses of aflibercept versus sham in patients with good visual acuity and no center-involving diabetic macular edema.
Switching to Intravitreal Aflibercept from other Anti-VEGF treatments
Investigators reported improvements in BCVA and in central subfield thickness, but noted decreases in superficial and deep capillary density.
No Benefit to Beginning Treatment Prior to Vision Loss in Most DME Cases
A recent study found that early intervention before vision loss does little for patients compared to those who do not receive preemptive treatment.
Charles Wykoff, MD, PhD: Context of the PANORAMA Trial
PANORAMA is the first prospective study of high-risk patients with non-proliferative diabetic retinopathy, but not DME, in the anti-VEGF era.
Association Between Chronic Conditions and Visual Impairment
After analyzing information from a cohort of more than 380,000, investigators found an association between chronic illnesses and visual impairment.
Increasing Awareness & Screening Efforts Against Diabetic Keratopathy
Approximately half of all patients with diabetes suffer from keratopathy, yet diagnoses are still underwhelming. Annual screenings need to become more standard.
Jason Hsu, MD: Outcomes of Switching from Aflibercept to Ranibizumab
Jason Hsu, MD, and his colleagues at the Wills Eye Hospital presented a study at ARVO 2019 regarding short-term outcomes of patients, with nAMD, who switched from afliberecept to ranibizumab.
Mia Woodward, MD: The Role of Telehealth in Ophthalmology
Mia Woodward, MD, discusses the future of telehealth in ophthalmology and the biggest issues that need to be corrected going forward.
Why Is Myasthenia Gravis So Difficult to Diagnose?
Deepak Bhatt, MD: Fighting Cardiovascular Disease
New Uterine Fibroids Oral Treatment Could Replace Surgery (UPDATE)
Interoperability Is the Key to a Patient-centric Transformation of the Healthcare System
John M. Kane, MD: The Benefits & Shortcomings of Schizophrenia Therapy
Affordable Care Act
PHYSICIAN'S MONEY DIGEST >
MD Magazine Resources
Terms & Conditions
Copyright© MD Magazine 2006-2019 Intellisphere, LLC. All Rights Reserved.